SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

14 May 2026 Evaluate
A decrease in the sales to Rs. 42099.80 millions was observed for the quarter ended March 2026. The sales stood at Rs. 47978.90 millions during the similar quarter previous year.A big decline of -74.11% was reported for the quarter ended March 2026 to Rs. 3846.40  millions from Rs. 14854.00 millions of corresponding previous quarter.Operating Profit reported a sharp decline to 7783.30 millions from 16120.80 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 42099.80 47978.90 -12.25 189799.50 190448.50 -0.34 189799.50 190448.50 -0.34
Other Income 1802.20 2933.70 -38.57 11226.50 9847.20 14.01 11226.50 9847.20 14.01
PBIDT 7783.30 16120.80 -51.72 55890.40 67631.60 -17.36 55890.40 67631.60 -17.36
Interest 67.40 34.90 93.12 193.00 151.10 27.73 193.00 151.10 27.73
PBDT 7715.90 19032.50 -59.46 53253.70 70427.10 -24.38 53253.70 70427.10 -24.38
Depreciation 2491.10 1477.00 68.66 6894.30 5738.90 20.13 6894.30 5738.90 20.13
PBT 5224.80 17555.50 -70.24 46359.40 64688.20 -28.33 46359.40 64688.20 -28.33
TAX 1378.40 2701.50 -48.98 11207.60 13111.70 -14.52 11207.60 13111.70 -14.52
Deferred Tax 180.70 -625.60 -128.88 188.60 -491.50 -138.37 188.60 -491.50 -138.37
PAT 3846.40 14854.00 -74.11 35151.80 51576.50 -31.85 35151.80 51576.50 -31.85
Equity 1615.60 1615.20 0.02 1615.60 1615.20 0.02 1615.60 1615.20 0.02
PBIDTM(%) 18.49 33.60 -44.98 29.45 35.51 -17.08 29.45 35.51 -17.08

Cipla Share Price

1387.50 -10.25 (-0.73%)
05-Jun-2026 10:36 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1789.25
Dr. Reddys Lab 1274.20
Cipla 1387.50
Zydus Lifesciences 1088.05
Lupin 2264.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×